LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | TGX221 | 0.12 | uM | LJP5 | 72 | hr | 868 | 2538 | 3410 | 0.7442 | 0.7213 |
MDA-MB-231 | TGX221 | 0.37 | uM | LJP5 | 72 | hr | 868 | 2555 | 3410 | 0.7490 | 0.7272 |
MDA-MB-231 | TGX221 | 1.11 | uM | LJP5 | 72 | hr | 868 | 2919 | 3410 | 0.8562 | 0.8489 |
MDA-MB-231 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 868 | 2001 | 3410 | 0.5868 | 0.5261 |
MDA-MB-231 | TGX221 | 10 | uM | LJP5 | 72 | hr | 868 | 2894 | 3410 | 0.8488 | 0.8406 |
MDA-MB-231 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3825 | 3410 | 1.1220 | 1.1204 |
MDA-MB-231 | GSK1059615 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3909 | 3556 | 1.1007 | 1.0969 |
MDA-MB-231 | GSK1059615 | 0.12 | uM | LJP5 | 72 | hr | 868 | 3699 | 3410 | 1.0848 | 1.0843 |
MDA-MB-231 | GSK1059615 | 0.12 | uM | LJP6 | 72 | hr | 868 | 3571 | 3556 | 1.0056 | 1.0057 |
MDA-MB-231 | GSK1059615 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3113 | 3410 | 0.9132 | 0.9103 |
MDA-MB-231 | GSK1059615 | 0.37 | uM | LJP6 | 72 | hr | 868 | 3102 | 3556 | 0.8743 | 0.8718 |
MDA-MB-231 | GSK1059615 | 1.11 | uM | LJP5 | 72 | hr | 868 | 1671 | 3410 | 0.4903 | 0.3935 |
MDA-MB-231 | GSK1059615 | 1.11 | uM | LJP6 | 72 | hr | 868 | 1919 | 3556 | 0.5397 | 0.4766 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 868 | 781 | 3410 | 0.2288 | -0.0542 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1178 | 3556 | 0.3310 | 0.1595 |
MDA-MB-231 | GSK1059615 | 10 | uM | LJP5 | 72 | hr | 868 | 586 | 3410 | 0.1717 | -0.1825 |
MDA-MB-231 | GSK1059615 | 10 | uM | LJP6 | 72 | hr | 868 | 660 | 3556 | 0.1856 | -0.1283 |
MDA-MB-231 | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 868 | 2841 | 3410 | 0.8315 | 0.8193 |
MDA-MB-231 | Brivanib | 0.12 | uM | LJP5 | 72 | hr | 868 | 2804 | 3410 | 0.8232 | 0.8118 |
MDA-MB-231 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2967 | 3410 | 0.8695 | 0.8622 |
MDA-MB-231 | Brivanib | 1.11 | uM | LJP5 | 72 | hr | 868 | 2996 | 3410 | 0.8785 | 0.8728 |
MDA-MB-231 | Brivanib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2782 | 3410 | 0.8136 | 0.7970 |
MDA-MB-231 | Brivanib | 10 | uM | LJP5 | 72 | hr | 868 | 2241 | 3410 | 0.6564 | 0.6149 |
MDA-MB-231 | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3091 | 3556 | 0.8691 | 0.8665 |
MDA-MB-231 | CHIR-99021 | 0.12 | uM | LJP6 | 72 | hr | 868 | 2799 | 3556 | 0.7880 | 0.7791 |